

KMAP GENERAL BULLETIN 18193

Histrelin Acetate Implant

Effective with dates of service on and after November 1, 2018, providers may bill the histrelin acetate implant (Supprelin[®] LA) for central precocious puberty for consideration of payment. The histrelin acetate implant will no longer be considered content of service for central precocious puberty.

Note: The effective date of the policy is November 1, 2018. The implementation of State policy by the KanCare managed care organizations (MCOs) may vary from the date noted in the Kansas Medical Assistance Program (KMAP) bulletins. The **KanCare Open Claims Resolution Log** on the KMAP [Bulletins](#) page documents the MCO system status for policy implementation and any associated reprocessing completion dates, once the policy is implemented.

KMAP[Kansas Medical Assistance Program](#)

- [Bulletins](#)
- [Manuals](#)
- [Forms](#)

Customer Service

- 1-800-933-6593
- 7:30 a.m. - 5:30 p.m.
Monday - Friday